Eli Lilly has secured approval from the Hong Kong government to market its tirzepatide injections, known commercially as Mounjaro, for both long-term weight management and the treatment of type 2 diabetes. The company plans to make the drug available in a user-friendly Kwikpen device, potentially launching sales as early as the end of this year, according to a statement released to Bloomberg News.
The approval marks a significant step for individuals in Hong Kong seeking pharmaceutical intervention for weight management and diabetes control. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated notable efficacy in clinical trials for both indications. The Kwikpen delivery system aims to provide a convenient and accessible option for patients.
Details regarding pricing and specific launch dates are expected to be released closer to the commercial availability of Mounjaro in Hong Kong.
